Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial.
- DOI
- 10.1136/bmjdrc-2020-001649
- Published
- 2020 Dec
- Container
- BMJ open diabetes research & care
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/bmjdrc-2020-001649,
title = {Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial.},
author = {Buse JB and Bode BW and Mertens A and Cho YM and Christiansen E and Hertz CL and Nielsen MA and Pieber TR and PIONEER 7 investigators},
year = {2020},
journal = {BMJ open diabetes research \& care},
doi = {10.1136/bmjdrc-2020-001649},
url = {https://doi.org/10.1136/bmjdrc-2020-001649}
}RIS
TY - JOUR TI - Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial. AU - Buse JB AU - Bode BW AU - Mertens A AU - Cho YM AU - Christiansen E AU - Hertz CL AU - Nielsen MA AU - Pieber TR AU - PIONEER 7 investigators PY - 2020 JO - BMJ open diabetes research & care DO - 10.1136/bmjdrc-2020-001649 UR - https://doi.org/10.1136/bmjdrc-2020-001649 ER -
APA
JB, B., BW, B., A, M., YM, C., E, C., CL, H., MA, N., TR, P., & investigators, P. 7. (2020). Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial.. BMJ open diabetes research & care. https://doi.org/10.1136/bmjdrc-2020-001649
Source records
- pubmed · retrieved 2026-09-27T00:40:56.857Z
- europe-pmc · retrieved 2026-09-27T00:40:56.864Z